ctDNA-based molecular residual disease and survival in resectable colorectal cancer
National Cancer Center Hospital East · Kansai Medical University · +22 more institutions
Abstract
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC). This updated analysis with a 23-month median follow-up, including 2,240 patients with stage II–III colon cancer or stage IV CRC, reinforces the prognostic value of ctDNA positivity during the MRD window with significantly inferior disease-free survival (DFS; hazard ratio (HR): 11.99, P
Citation impact
- FWCI
- 45.47
- Percentile
- 100%
- References
- 23
Authors
36- YNYoshiaki NakamuraCorresponding
National Cancer Center Hospital East
- JWJun Watanabe
Kansai Medical University, Yokohama City University Medical Center, Yokohama City University
- NANaoya Akazawa
Sendai Medical Center
- KHKeiji Hirata
University of Occupational and Environmental Health Japan
- KKKozo Kataoka
Kobe Medical Center, Kobe University
Topics & keywords
- Medicine
- Colorectal cancer
- Internal medicine
- Oncology
- Hazard ratio
- Stage (stratigraphy)
- Adjuvant therapy
- Circulating tumor DNA
- Good health and well-being